Trial site
Clinica de Investigacion en Reumatologia y Obesidad S. C.
- 10running trials
- 5closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Conditions
- Lupus (SLE)3 trials
- Ulcerative colitis3 trials
- Obesity2 trials
- Alopecia areata1 trial
- Asthma1 trial
- Bipolar disorder1 trial
- Depression1 trial
- Irritable bowel syndrome1 trial
- Obstructive sleep apnoea1 trial
- Osteoarthritis1 trial
- Type 2 diabetes1 trial
- Phase
- Phase 27 trials
- Phase 36 trials
- Phase 2/32 trials
- Status
- Recruiting5 trials
- Completed4 trials
- Active, not recruiting2 trials
- Not yet recruiting2 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company10 trials
- Biogen2 trials
- Pfizer2 trials
- Genentech, Inc.1 trial
Running trials
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Recruiting
Recruiting
Recruiting
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Ulcerative colitis3 recruiting
- Asthma1 recruiting
- Bipolar disorder1 recruiting
- Depression1 recruiting
- Irritable bowel syndrome1 recruiting
- Lupus (SLE)1 recruiting
Closed trials
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Terminated
Completed
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Completed
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
Completed
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Site data: ClinicalTrials.govUpdated 17 Nov 2026